A Phase II Open-Label Study of SH L 749 in Relapsed or Refractory Indolent B-Cell Non-Hodgkin's Lymphomas
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Best overall response rates (the percentage of patients who achieved PR or better response)
After 9 weeks or 13 weeks
Bayer Study Director
Japan: Ministry of Health, Labor and Welfare